“You can't just have all or none treatments. You've got to have a middle ground for people who are going to look for that,” says John R. Valvo, MD.
In this video, John R. Valvo, MD, discusses an example of a potential candidate for high-intensity focused ultrasound treatment. Valvo is Director of Robotics at Rochester Regional Health in Rochester, New York, a clinical associate professor and Chief of Urology for Via Health in Rochester, and Executive Director of the Polissini Center for Robotic and Minimally Invasive Surgery at Rochester General Hospital. GO-3
FDA approves olaparib/abiraterone for BRCA-positive mCRPC
The phase 3 PROpel trial provided the primary supporting data for the approval.
Dr. Kishan highlights findings from the MIRAGE trial in prostate cancer
Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.
Managing aging and frailty in the urologic cancer population
Increasing numbers of older patients with cancer necessitates adoption of an age-friendly approach to cancer care.
Dr. Laviana on decisional regret after prostate cancer treatment
“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.
Improving immune responses in prostate cancer
Men with high-risk prostate cancer who received immunotherapy treatment with enoblituzumab in the weeks leading up to surgery had favorable rates of disease remission and tumor downgrading after surgery.
Progress in invasive and advanced bladder cancer: shooting for the moon
ND YAG laser machine "We anticipate that in the next decade, breakthroughs in genetic profiling of tumors for precision therapies will further reduce suffering and death from bladder cancer," writes Michael S. Cookson, MD, MMHC.